Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.60 |
| ▸ | NPC1 | O15118 | 4/20 | 0.60 |
| ▸ | RAB9A | P51151 | 4/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | POLB | P06746 | 3/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.60 |
| ▸ | CASP3 | P42574 | 2/20 | 0.60 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.60 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.57 |
| ▸ | TTR | P02766 | 1/20 | 0.56 |
| ▸ | ALB | P02768 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1675540 | 0.97 | HDAC6 (0.71) | HDAC6SMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL9797021 | 0.94 | HDAC6 (0.65) | HDAC6SMN1; SMN2RAB9ATP53MAPT | |
| SCHEMBL13135790 | 0.92 | HDAC6 (0.63) | HDAC6SMN1; SMN2RAB9ATP53MAPT | |
| SCHEMBL1675525 | 0.91 | HDAC6 (0.63) | HDAC6SMN1; SMN2NPC1RAB9AALDH1A1 | |
| Hydrochloric Acid SCHEMBL17985190 | 0.91 | HDAC6 (0.62) | HDAC6SMN1; SMN2RAB9ATP53MAPT | |
| SCHEMBL1675372 | 0.90 | HDAC6 (0.65) | HDAC6SMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL23717214 | 0.88 | HDAC6 (0.71) | HDAC6SMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL12171536 | 0.88 | HDAC6 (0.63) | HDAC6SMN1; SMN2RAB9ATP53MAPT | |
| SCHEMBL14326101 | 0.88 | HDAC6 (0.70) | HDAC6SMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL19945200 | 0.88 | HDAC6 (0.71) | HDAC6SMN1; SMN2NPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110195932-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | SUMMIT (OXFORD) LIMITED (GB) | 2011-08-11 | — | — | US | claimed |
| CN-100448852-C | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | SCRIPPS RESEARCH INST (US) | 2009-01-07 | — | — | CN | claimed |
| EP-1587821-B1 | COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING | SCRIPPS RESEARCH INST (US) | 2008-08-20 | — | — | EP | claimed |
| US-7214696-B2 | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-05-08 | — | — | US | claimed |
| US-20060057644-A1 | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | SCRIPPS RESEARCH INSTITUTE, THE | 2006-03-16 | — | — | US | claimed |
| US-11390610-B2 | Piperazine derivatives as MAGL inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2022-07-19 | — | — | US | disclosed |
| EP-3694840-B1 | PIPERAZINE DERIVATIVES AS MAGL INHIBITORS | HOFFMANN LA ROCHE (CH) | 2021-08-04 | — | — | EP | disclosed |
| US-20200299277-A1 | PIPERAZINE DERIVATIVES AS MAGL INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2020-09-24 | — | — | US | disclosed |
| CN-109180590-A | A method of Benzoheterocyclic compounds are quickly prepared using physical grinding method under room temperature solvent-free | 福建医科大学 | 2019-01-11 | — | — | CN | disclosed |
| EP-3251694-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Summit (Oxford) Limited (GB) | 2017-12-06 | — | — | EP | disclosed |
| EP-2325651-B1 | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | SCRIPPS RESEARCH INST (US) | 2014-10-08 | — | — | EP | disclosed |
| EP-1986633-B1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORP PLC (GB) | 2014-07-30 | — | — | EP | disclosed |
| US-7214696-B2 | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-05-08 | — | — | US | disclosed |
| US-7214695-B2 | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-05-08 | — | — | US | disclosed |
| US-20070078186-A1 | Methods for treating transthyretin amyloid diseases | THE SCRIPPS RESEARCH INSTITUTE | 2007-04-05 | — | — | US | disclosed |
| US-20060057644-A1 | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | SCRIPPS RESEARCH INSTITUTE, THE | 2006-03-16 | — | — | US | disclosed |
| CN-1747965-A | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | SCRIPPS RESEARCH INST (US) | 2006-03-15 | — | — | CN | disclosed |
| EP-1587821-A2 | COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING | The Scripps Research Institute (US) | 2005-10-26 | — | — | EP | disclosed |
| US-20040152140-A1 | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | THE SCRIPPS RESEARCH INSTITUTE | 2004-08-05 | — | — | US | disclosed |
| WO-2004056315-A2 | COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING | THE SCRIPPS RESEARCH INSTITUTE (US) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078186-A1 | Methods for treating transthyretin amyloid diseases | TTR, TTPA, PRNP | HDAC6 2617/4885SMN1; SMN2 239/4885NPC1 336/4885 |
| US-20110195932-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | PYGM, CPT1B, GYS1 | HDAC6 97/4885SMN1; SMN2 4/4885NPC1 2477/4885 |
| US-11390610-B2 | Piperazine derivatives as MAGL inhibitors | MAGI3, PYM1, MAG | HDAC6 539/4885SMN1; SMN2 1928/4885NPC1 509/4885 |
| US-20200299277-A1 | PIPERAZINE DERIVATIVES AS MAGL INHIBITORS | MAGI3, PYM1, MAG | HDAC6 539/4885SMN1; SMN2 1928/4885NPC1 509/4885 |
| US-20060057644-A1 | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | TTR, TTPA, PRNP | HDAC6 3685/4885SMN1; SMN2 280/4885NPC1 367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.